Go
Your browser has Javascript disabled, so some things may not quite work how they should on LI right now: please enable JavaScript in your browser to fix things, we have no nefarious trackers, or scripts by Facebook, Google or others.
In Brief
Thursday, 13 May 2021 18:17 Private equity / VC
Zydus Animal Health and Investments Limited (ZAHL) a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium.
For lump sum consideration of Rs 2921 croreZydus Animal Health and Investments (ZAHL) a wholly owned material subsidiary of Cadila Healthcare, has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements (Definitive Agreements) to sell and transfer its Animal Healthcare Established Markets Undertaking (Undertaking or Zydus AH) to Multiples Alternate Asset Management (Multiples) led consortium.
Zydus AH is the animal health business of ZAHL focused on India and certain other countries. The consortium, including Canada Pension Plan Investment Board (CPP Investments) and RARE Enterprises (RARE), has agreed to purchase the Undertaking through an SPV controlled by them, in the name of Zenex Animal Health India.
Cadila Healthcare rose 2.60% to Rs 646.10 after the company s subsidiary announced plans to sell its India focused animal health business to Multiples Alternate Asset Management led consortium.
Zydus Animal Health and Investments (ZAHL), a wholly owned material subsidiary of Cadila Healthcare, has entered into a business transfer agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking (Zydus AH) to Multiples Alternate Asset Management led consortium.
The deal is to sell one of the two business undertakings of ZAHL, called Animal Healthcare Established Markets Undertaking on a slump sale basis as a going concern, for a lump sum consideration of Rs 2,921 crore on a cash free and debt free basis, subject to certain closing date adjustments and other conditions.
Cadila Healthcare Ltd (Zydus Cadila) s wholly-owned material subsidiary Zydus Animal Health and Investments Limited (ZAHL) is set to sell its animal healthcare business to a consortium led by Multiples Alternate Asset Management for nearly Rs 3,000 crore.
Zydus Cadila on Wednesday announced that ZAHL has entered into a business transfer agreement (BTA) and other ancillary agreements to sell and transfer Zydus AH, its animal healthcare established markets undertaking to the Multiples-led consortium. The deal is to sell one of the two business undertakings of ZAHL on a slump sale basis as a going concern, for a lump sum consideration of Rs 2,921 crore on a cash-free and debt-free basis, subject to certain closing date adjustments and other conditions. The transaction involves transfer of immovable assets, movable assets, inventory, brands and intangible assets, contracts, licenses and permissions, business records, employees along with employee benefit funds, insurance policies, ot
Cadila Healthcare share hits 52-week high as firm to sell animal health business
The consortium, including Canada Pension Plan Investment Board and Rakesh Jhunjhunwala-backed RARE Enterprises, has agreed to purchase the Undertaking through an SPV controlled by them, in the name of Zenex Animal Health India Private Limited for Rs 2,921 crore
BusinessToday.In | May 12, 2021 | Updated 18:06 IST
Representative Image
Share of Cadila Healthcare rose nearly 7 per cent to hit a 52-week high after the company announced that Zydus Animal Health and Investments Limited (ZAHL), a wholly-owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium.